Edwards Lifesciences Corporation logo EW - Edwards Lifesciences Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 32
HOLD 16
SELL 0
STRONG
SELL 0
| PRICE TARGET: $98.90 DETAILS
HIGH: $110.00
LOW: $85.00
MEDIAN: $97.50
CONSENSUS: $98.90
UPSIDE: 7.26%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Strong
Trading 77.5% above fair value
Current Price $92.21
Bear Case $41.55 54.9% downside ($41.55 - $92.21) / $92.21 = -54.9% $1.99 × 13x P/E
Fair Value $51.95 43.7% downside ($51.95 - $92.21) / $92.21 = -43.7% $1.99 × 16x P/E
Bull Case $62.35 32.4% downside ($62.35 - $92.21) / $92.21 = -32.4% $1.99 × 19x P/E

Adjust Assumptions

16.0x
1.99$

Key Value Driver

Normalized P/E multiple (16x base case)

Implied Market Multiple 46.3x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $98.90 from 48 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $51.95 per share.

Warnings

ℹ Wall Street's average price target is $98.90 (from 48 analysts). Our estimate is 68% below the consensus -- consider that gap carefully.

Key Risks

  • Growth DCF inappropriate — terminal value assumptions dominate
  • EV/EBITDA misleading for regulated businesses where capex is mandated
  • Regulatory risk is a fat tail not visible in normal multiples